BridgeBio Pharma CEO Neil Kumar Sells $691K in Common Stock Under 10b5-1 Plan
BridgeBio Pharma, Inc.
Subscribe to track BBIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BridgeBio Pharma, Inc. ($BBIO) - Insider Sale Reported
• Insider: Neil Kumar (Chief Executive Officer, Director) • Transaction: Sold 10,000 shares of Common Stock at an average price of ~$69.08 per share • Total Value: $690,847.12 • Transaction Date: 2026-09-17 • Filing Date: 2026-09-21 • Plan: Rule 10b5-1 sales plan adopted on May 13, 2026 • Remaining Position: 495,686 shares (in selling trust); over 5.05M total shares held across direct and indirect holdings.
Comprehensive Analysis
Executive Summary
On September 21, 2026, BridgeBio Pharma, Inc. ($BBIO) Chief Executive Officer and Director Neil Kumar filed a Form 4 disclosing the sale of 10,000 shares of common stock executed on September 17, 2026. The transaction generated approximately $690,847 in gross proceeds at a weighted average price of ~$69.08 across two tranches ($69.0136 and $69.5696).
Transaction Details
- Seller: Neil Kumar (CEO & Director)
- Nature of Ownership: Indirect, held via the Kumar Haldea Family Irrevocable Trust (co-trustee).
- Tranche 1: 8,721 shares at a weighted average price of $69.0136 (range: $68.52 – $69.40).
- Tranche 2: 1,279 shares at a weighted average price of $69.5696 (range: $69.525 – $69.64).
- Total Volume: 10,000 shares
- Total Consideration: $690,847.12
- 10b5-1 Plan: Executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 13, 2026.
Holdings Context
Following the transactions, Dr. Kumar continues to hold extensive equity in BridgeBio Pharma across multiple vehicles:
- Kumar Haldea Family Irrevocable Trust: 495,686 shares
- Kumar Haldea Revocable Trust: 3,568,447 shares
- NK 2026 GRAT: 750,000 shares
- Direct Ownership: 243,327 shares
- Total Beneficial Ownership: 5,057,460 shares
The 10,000 shares sold represent less than 0.2% of Dr. Kumar's total direct and indirect equity exposure.
Market Sentiment & Significance
The transaction is rated as Low significance due to:
- Execution under a pre-established Rule 10b5-1 trading plan.
- Routine programmatic volume representing a negligible portion of total holdings.
- Retention of over 5 million shares, maintaining full alignment with long-term shareholder value.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.